Marty Makary resigns as FDA commissioner following industry and White House backlash
Coveragetap to expand ▾Spectrum: Mixed🌍US: 6 · Other: 4
- Makary's tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers, physicians and patient groups on regulatory decisions.
- In a post on Truth Social, President Donald Trump said Kyle Diamantas, who previously worked as the top food official at the FDA, will step in as acting commissioner.
- A senior administration official confirmed that Makary resigned on Tuesday, following days of reporting that the White House was planning to fire him.
- Trump Is Planning to Fire FDA Commissioner Marty Makary
Marty Makary resigned as FDA commissioner on May 8, 2026, amid mounting pressure from both the pharmaceutical industry and the White House. His resignation follows a series of controversies and criticisms regarding regulatory decisions that have drawn ire from drugmakers, physicians, and patient advocacy groups.
Reports suggest that internal dysfunction and leadership turmoil plagued the FDA during Makary's tenure, leading to a lack of confidence in the agency's ability to effectively manage its responsibilities. President Donald Trump confirmed that Kyle Diamantas, who previously served as the top food official at the FDA, will take over as acting commissioner.
The White House had reportedly been preparing to remove Makary prior to his resignation, indicating a significant rift between the FDA and the administration. This situation underscores the challenges facing the FDA as it navigates complex relationships with industry stakeholders while attempting to maintain public trust in its regulatory processes.
The future direction of the agency under Diamantas will be closely watched, especially as it seeks to address the criticisms that have emerged during Makary's controversial leadership.
- Marty Makary's resignation as FDA Commissioner underscores the ongoing tensions between regulatory bodies and the pharmaceutical industry, which could lead to delays in critical drug approvals and impact patient access to new treatments.
- With Kyle Diamantas stepping in as acting commissioner, stakeholders—including drugmakers, healthcare providers, and patients—will be closely watching how this leadership change affects regulatory policies and the FDA's responsiveness to public health needs.
- The shift in leadership may also signal a potential pivot in the FDA's approach to drug regulation, which could either alleviate or exacerbate existing frustrations among those reliant on timely access to medications.
- Watch for the White House to announce a new candidate for FDA commissioner within the next two weeks, as they seek to stabilize leadership amid ongoing industry scrutiny.
- Expect major pharmaceutical companies to release statements regarding their regulatory strategies in response to Makary's resignation within the next 72 hours.
- Keep an eye on Congress, as lawmakers may hold hearings to address the implications of this leadership change on drug approval processes before the upcoming legislative session.
- Monitor public health advocacy groups, which are likely to issue reports or position statements on the future direction of the FDA within the next month.
- Anticipate potential stock market reactions from biotech firms as they adjust to the leadership vacuum at the FDA during the next quarterly earnings reports.
Left- and right-leaning outlets are covering this story differently — in which facts to emphasize, which context to include, and how to frame causes and consequences.